Literature DB >> 8786007

Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers.

H U Jahn1, R Ullrich, T Schneider, R M Liehr, H L Schieferdecker, H Holst, M Zeitz.   

Abstract

Saccharomyces boulardii (S.b.) is used for the prevention and treatment of diarrhea of different etiologies. We prospectively investigated the effects of S.b. on lymphocytes and duodenal mucosa. Before and after oral administration of S.b. for 3 weeks, circulating and intestinal lymphocytes were isolated and characterized by flow cytometry. Trophic effects on duodenal mucosa were investigated by morphometry and determination of brush border enzyme activity. Results were compared intraindividually before and after S.b. In intestinal lymphocytes no phenotypic changes were observed. CD4+ cells of the peripheral blood had a significantly increased expression of CD25 (p < 0.02). None of twelve volunteers had an increase in villous surface area (n.s.). Immunoglobulin A content in small intestine secretion was unaltered. An increase in brush border enzyme activity of lactase, alpha-glucosidase, and alkaline phosphatase was observed (p < 0.01). Our findings indicate that S.b. has a positive effect on the maturation of enterocytes and only a minor influence on lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786007     DOI: 10.1159/000201320

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  21 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice.

Authors:  Benoît Foligné; Joëlle Dewulf; Pascal Vandekerckove; Georges Pignède; Bruno Pot
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

Review 3.  Ecological Therapeutic Opportunities for Oral Diseases.

Authors:  Anilei Hoare; Philip D Marsh; Patricia I Diaz
Journal:  Microbiol Spectr       Date:  2017-08

4.  From Birth and Throughout Life: Fungal Microbiota in Nutrition and Metabolic Health.

Authors:  William D Fiers; Irina Leonardi; Iliyan D Iliev
Journal:  Annu Rev Nutr       Date:  2020-07-17       Impact factor: 11.848

Review 5.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 6.  Effects of Saccharomyces boulardii on intestinal mucosa.

Authors:  Jean-Paul Buts; Nadine De Keyser
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

7.  Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii.

Authors:  Tom Vanhoutte; Vicky De Preter; Evie De Brandt; Kristin Verbeke; Jean Swings; Geert Huys
Journal:  Appl Environ Microbiol       Date:  2006-09       Impact factor: 4.792

8.  Studies on the time course of the effects of the probiotic yeast Saccharomyces boulardii on electrolyte transport in pig jejunum.

Authors:  B Schroeder; C Winckler; K Failing; G Breves
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

9.  Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.).

Authors:  M J McCullough; K V Clemons; J H McCusker; D A Stevens
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis.

Authors:  Fariborz Mansour-Ghanaei; Najaf Dehbashi; Kamyar Yazdanparast; Afshin Shafaghi
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.